Tedatioxetine

Tedatioxetine
Clinical data
Other names	Lu AA24530; Lu-AA-24530
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine;
CAS Number	508233-95-2 ;
PubChem CID	9878913;
ChemSpider	8054590 ;
UNII	5H681S8O3S;
KEGG	D10170 ;
Chemical and physical data
Formula	C18H21NS
Molar mass	283.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2;
	InChI InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3 ; Key:CVASBKDYSQKLSO-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tedatioxetine (Lu AA24530) is an antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]

Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and 5-HT_2A, 5-HT_2C, 5-HT₃ and α_1A-adrenergic receptor antagonist.[2][3][4][5]

As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[6][7]

On May 10, 2016, all work on tedatioxetine stopped.[8]

A Sino Patent manages to show that there has been interest in this compound outside of Lundbeck: WO 2015090160

References

Beaulieu D (5 September 2007). "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]". First Word Pharma.
US 2010144788, Stensbol TB, Miller S, "4-[2-(4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression", published 10 June 2010, assigned to H Lundbeck AS
Stahl SM (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
Stolerman IP (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
"Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009.
"Pipeline of Lundbeck". Retrieved 25 August 2013.
"Tedatioxetine". UK Medicines Information. Retrieved 20 January 2016.
"Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. Retrieved 2016-06-09.

External links

Lu AA24530 shows positive results in major depressive disorder phase II study

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Beaulieu D (5 September 2007). "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]". First Word Pharma.

[urlUSPTO20100144788-2] US 2010144788, Stensbol TB, Miller S, "4-[2-(4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression", published 10 June 2010, assigned to H Lundbeck AS

[Stahl2008-3] Stahl SM (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.

[Stolerman2010-4] Stolerman IP (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.

[Fierce-5] "Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009.

[urlPipeline_of_Lundbeck-6] "Pipeline of Lundbeck". Retrieved 25 August 2013.

[7] "Tedatioxetine". UK Medicines Information. Retrieved 20 January 2016.

[8] "Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. Retrieved 2016-06-09.

Tedatioxetine

See also

References

External links